newsfilter
← Latest News
Business Wire·

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

VE202 was well tolerated, with no reports of treatment-related serious adverse events Additional analyses from COLLECTiVE202 to be shared in upcoming scientific forums Vedanta to focus resources on ongoing Phase 3